• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

针对人巨细胞病毒糖蛋白B(gpUL55)抗原结构域1的特异性抗体与不同的亚结构结合。

Antibodies specific for the antigenic domain 1 of glycoprotein B (gpUL55) of human cytomegalovirus bind to different substructures.

作者信息

Schoppel K, Hassfurther E, Britt W, Ohlin M, Borrebaeck C A, Mach M

机构信息

Institut für Klinische und Molekulare Virologie, Universität Erlangen-Nürnberg, Germany.

出版信息

Virology. 1996 Feb 1;216(1):133-45. doi: 10.1006/viro.1996.0040.

DOI:10.1006/viro.1996.0040
PMID:8614980
Abstract

Glycoprotein B (gB, gpUL55) is a major antigen for the induction of neutralizing antibodies against human cytomegalovirus, making it an attractive antigen for active and passive immunoprophylaxis. The immunodominant region on gB is the antigenic domain 1 (AD-1), a complex structure which requires a minimal linear amino acid sequence of more than 75 amino acids (aa 552-635) for antibody binding. We have analyzed the fine specificity of neutralizing and nonneutralizing AD-1-binding monoclonal antibodies. Point mutations were introduced into AD-1 and mutants were expressed as bacterial fusion proteins. The antigens were analyzed in immunoblots using a panel of 13 human and murine monoclonal antibodies. Complete loss of binding of all antibodies was observed with mutations at cysteine residues 573 and 610 as well as with a combinatorial exchange of prolines at position 577 and 613. The remaining mutations had different effects on antibody binding. Six individual recognition patterns were observed, indicating various antigenic substructures on AD-1. Changing the Fc portions of 3 murine monoclonal antibodies to human IgG1 showed that neutralization of AD-1-binding immunoglobulins is exerted by different mechanisms. Dependent on the recognized substructure within AD-1, avidity-dependent as well as Fc portion-mediated effects were observed.

摘要

糖蛋白B(gB,gpUL55)是诱导针对人巨细胞病毒的中和抗体的主要抗原,使其成为主动和被动免疫预防的有吸引力的抗原。gB上的免疫显性区域是抗原结构域1(AD-1),这是一种复杂结构,抗体结合需要至少75个氨基酸的最小线性氨基酸序列(第552-635位氨基酸)。我们分析了中和及非中和性AD-1结合单克隆抗体的精细特异性。将点突变引入AD-1,并将突变体表达为细菌融合蛋白。使用一组13种人源和鼠源单克隆抗体在免疫印迹中分析抗原。在半胱氨酸残基573和610处发生突变以及在第577和613位脯氨酸的组合交换时,观察到所有抗体的结合完全丧失。其余突变对抗体结合有不同影响。观察到六种个体识别模式,表明AD-1上存在各种抗原亚结构。将3种鼠源单克隆抗体的Fc部分改为人类IgG1表明,AD-1结合免疫球蛋白的中和作用是通过不同机制发挥的。根据AD-1内识别的亚结构,观察到了亲和力依赖性以及Fc部分介导的效应。

相似文献

1
Antibodies specific for the antigenic domain 1 of glycoprotein B (gpUL55) of human cytomegalovirus bind to different substructures.针对人巨细胞病毒糖蛋白B(gpUL55)抗原结构域1的特异性抗体与不同的亚结构结合。
Virology. 1996 Feb 1;216(1):133-45. doi: 10.1006/viro.1996.0040.
2
Antigenic domain 1 of human cytomegalovirus glycoprotein B induces a multitude of different antibodies which, when combined, results in incomplete virus neutralization.人巨细胞病毒糖蛋白B的抗原结构域1可诱导产生多种不同抗体,这些抗体联合作用时会导致病毒中和不完全。
J Gen Virol. 1999 Aug;80 ( Pt 8):2183-2191. doi: 10.1099/0022-1317-80-8-2183.
3
Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus.登革2型病毒包膜蛋白结构域III(ED3)上一个包含显性、型特异性中和决定簇的抗原位点的特征分析
Virology. 2007 Sep 30;366(2):349-60. doi: 10.1016/j.virol.2007.05.042. Epub 2007 Aug 23.
4
Identification of a variant A-specific neutralizing epitope on glycoprotein B (gB) of human herpesvirus-6 (HHV-6).人疱疹病毒6型(HHV-6)糖蛋白B(gB)上一个变异A特异性中和表位的鉴定。
Virology. 1996 Aug 1;222(1):176-83. doi: 10.1006/viro.1996.0408.
5
Humoral immune response to functional regions of human cytomegalovirus glycoprotein B.针对人巨细胞病毒糖蛋白B功能区的体液免疫反应。
J Med Virol. 1997 Aug;52(4):451-9.
6
Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence.登革2型病毒(DEN2)包膜蛋白上一个中和表位的突变分析:抗单克隆抗体的DEN2/DEN4嵌合体显示小鼠神经毒力降低。
Virology. 1996 Oct 15;224(2):437-45. doi: 10.1006/viro.1996.0550.
7
Clonal repertoire diversification of a neutralizing cytomegalovirus glycoprotein B-specific antibody results in variants with diverse anti-viral properties.一种中和性巨细胞病毒糖蛋白B特异性抗体的克隆谱系多样化产生了具有不同抗病毒特性的变体。
Mol Immunol. 2007 Feb;44(5):680-90. doi: 10.1016/j.molimm.2006.04.024. Epub 2006 Jul 7.
8
Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica.登革2型病毒包膜糖蛋白的单克隆抗体定位,牙买加。
Virology. 1998 Jul 5;246(2):317-28. doi: 10.1006/viro.1998.9200.
9
Antigenic domain 1 is required for oligomerization of human cytomegalovirus glycoprotein B.人巨细胞病毒糖蛋白B的寡聚化需要抗原结构域1。
J Virol. 2005 Apr;79(7):4066-79. doi: 10.1128/JVI.79.7.4066-4079.2005.
10
Non-germ-line encoded residues are critical for effective antibody recognition of a poorly immunogenic neutralization epitope on glycoprotein B of human cytomegalovirus.非种系编码残基对于有效识别人类巨细胞病毒糖蛋白B上免疫原性较差的中和表位的抗体至关重要。
Eur J Immunol. 2002 Jun;32(6):1659-69. doi: 10.1002/1521-4141(200206)32:6<1659::AID-IMMU1659>3.0.CO;2-9.

引用本文的文献

1
Complete cross strain protection against congenital cytomegalovirus infection requires a vaccine encoding key antibody (gB) and T-cell (immediate early 1 protein) viral antigens.针对先天性巨细胞病毒感染实现完全的交叉毒株保护需要一种编码关键抗体(gB)和T细胞(即刻早期1蛋白)病毒抗原的疫苗。
bioRxiv. 2025 Jun 20:2025.06.18.660432. doi: 10.1101/2025.06.18.660432.
2
A human cytomegalovirus prefusion-like glycoprotein B subunit vaccine elicits humoral immunity similar to that of postfusion gB in mice.一种人巨细胞病毒预融合样糖蛋白B亚基疫苗在小鼠中引发的体液免疫与融合后gB相似。
J Virol. 2025 Jun 17;99(6):e0217824. doi: 10.1128/jvi.02178-24. Epub 2025 May 8.
3
The Autonomous Fusion Activity of Human Cytomegalovirus Glycoprotein B Is Regulated by Its Carboxy-Terminal Domain.
人巨细胞病毒糖蛋白 B 的自主融合活性受其羧基末端结构域调控。
Viruses. 2024 Sep 18;16(9):1482. doi: 10.3390/v16091482.
4
Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth.多价巨细胞病毒糖蛋白B核苷修饰mRNA疫苗并未显示出更广泛的抗体谱。
NPJ Vaccines. 2024 Feb 20;9(1):38. doi: 10.1038/s41541-024-00821-3.
5
Heterosubtypic, cross-reactive immunity to human Cytomegalovirus glycoprotein B.对人巨细胞病毒糖蛋白 B 的异亚型、交叉反应性免疫。
Clin Exp Immunol. 2022 Jun 11;208(2):245-254. doi: 10.1093/cei/uxac031.
6
Neutralizing Antibodies Limit Cell-Associated Spread of Human Cytomegalovirus in Epithelial Cells and Fibroblasts.中和抗体限制人巨细胞病毒在表皮细胞和成纤维细胞中的细胞相关传播。
Viruses. 2022 Jan 28;14(2):284. doi: 10.3390/v14020284.
7
Pre-existing immunity to cytomegalovirus in macaques influences human CMV vaccine responses in preclinical models.在灵长类动物中预先存在的巨细胞病毒免疫会影响临床前模型中人类巨细胞病毒疫苗的反应。
Vaccine. 2021 Sep 7;39(38):5358-5367. doi: 10.1016/j.vaccine.2021.08.011. Epub 2021 Aug 13.
8
Prefusion structure of human cytomegalovirus glycoprotein B and structural basis for membrane fusion.人巨细胞病毒糖蛋白B的前融合结构与膜融合的结构基础
Sci Adv. 2021 Mar 5;7(10). doi: 10.1126/sciadv.abf3178. Print 2021 Mar.
9
The N-terminus of varicella-zoster virus glycoprotein B has a functional role in fusion.水痘带状疱疹病毒糖蛋白 B 的 N 端在融合中具有功能作用。
PLoS Pathog. 2021 Jan 7;17(1):e1008961. doi: 10.1371/journal.ppat.1008961. eCollection 2021 Jan.
10
Rationally designed Human Cytomegalovirus gB nanoparticle vaccine with improved immunogenicity.具有增强免疫原性的合理设计的人巨细胞病毒gB纳米颗粒疫苗。
PLoS Pathog. 2020 Dec 28;16(12):e1009169. doi: 10.1371/journal.ppat.1009169. eCollection 2020 Dec.